Clinical trial
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study
NCT01119599 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2010
- Completion date
- Not reported
- Enrollment
- 22 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
acoustic schwannoma, adult anaplastic (malignant) meningioma, adult anaplastic astrocytoma, adult anaplastic ependymoma, adult brain stem glioma, adult choroid plexus neoplasm, adult craniopharyngioma, adult diffuse astrocytoma, adult ependymoblastoma, adult ependymoma, adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, adult grade i meningioma, adult grade ii meningioma, adult medulloblastoma, adult mixed glioma, adult myxopapillary ependymoma, adult oligodendroglioma, adult papillary meningioma, adult pilocytic astrocytoma, adult pineal gland astrocytoma, adult pineoblastoma, adult pineocytoma, adult primary melanocytic lesion of meninges, adult subependymal giant cell astrocytoma, adult subependymoma, adult supratentorial primitive neuroectodermal tumor, malignant adult intracranial hemangiopericytoma